Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Robb

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry|October 22, 2020
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitorsSébastien L Degorce, Anna Aagaard, Rana Anjum, et al.
Journal of Medicinal Chemistry|February 2, 2024
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390Kurt G Pike, Thomas A Hunt, Bernard Barlaam, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Journal of Medicinal Chemistry|August 12, 2024
Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug DesignTaylor R Quinn, Kathryn A Giblin, Clare Thomson, et al.
Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.
Nature Chemical Biology|October 25, 2016
Potent and selective bivalent inhibitors of BET bromodomainsMichael J Waring, Huawei Chen, Alfred A Rabow, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacologyJeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry|October 22, 2020
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitorsSébastien L Degorce, Anna Aagaard, Rana Anjum, et al.
Journal of Medicinal Chemistry|February 2, 2024
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390Kurt G Pike, Thomas A Hunt, Bernard Barlaam, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Journal of Medicinal Chemistry|August 12, 2024
Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug DesignTaylor R Quinn, Kathryn A Giblin, Clare Thomson, et al.
Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.
Nature Chemical Biology|October 25, 2016
Potent and selective bivalent inhibitors of BET bromodomainsMichael J Waring, Huawei Chen, Alfred A Rabow, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacologyJeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
Pageof 8